Shopping Cart

Remove All

Your shopping cart is currently empty

Proceed to checkout Continue shopping

MK-4256

Name: MK-4256
Brand: TargetMol
SKU: T16095
Rating: 4.5 (1 reviews)

😃Good

Catalog No. T16095Cas No. 1104599-69-0

MK-4256 is an effective and selective SSTR3 antagonist (IC50s: 0.66 nM and 0.36 nM in human and mouse receptor binding assays, respectively).

MK-4256

😃Good

Catalog No. T16095Cas No. 1104599-69-0

MK-4256 is an effective and selective SSTR3 antagonist (IC50s: 0.66 nM and 0.36 nM in human and mouse receptor binding assays, respectively).

Pack Size	Price	USA Warehouse	Global Warehouse
25 mg	$3,970	6-8 weeks	6-8 weeks
50 mg	$5,550	6-8 weeks	6-8 weeks
100 mg	$7,490	6-8 weeks	6-8 weeks

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Resource Download

Product Introduction

Bioactivity

Description	MK-4256 is an effective and selective SSTR3 antagonist (IC50s: 0.66 nM and 0.36 nM in human and mouse receptor binding assays, respectively).
Targets&IC50	SST3 receptor (human):0.66 nM, SST3 receptor (mouse):0.36 nM
In vitro	MK-4256 is tested in functional antagonist assays against SSTR4 and SSTR5. The IC50 values are greater than 5 μM (at least 5000-fold selectivity)[1]. MK-4256 inhibits radiolabeled MK-499 binding of the hERG channel (IC50=1.74 μM). MK-4256 has excellent selectivity against other SSTR subtypes based on in vitro assays and it also has IC50s >2 μM for SSTR1 and SSTR2, in human receptor binding assays. Although the binding IC50 values on SSTR4 and SSTR5 are below 1 μM, there is still >500-fold selectivity. MK-4256 exhibits 50% blockade of hERG at 3.4 μM concentration, in a functional patch-clamp assay[2].
In vivo	MK-4256 decreases the glucose excursion from 0.003 to 10 mg/kg in a dose-dependent manner. MK-4256 decreases glucose excursion in a dose-dependent fashion with maximal efficacy achieves at doses of MK-4256 (0.03 mg/kg; p.o.) demonstrates exceptional SSTR3-mediated glucose-lowering efficacy in the mouse oGTT model with minimal hypoglycemia risk. MK-4256 (1 mg/kg; p.o.) achieves complete ablation of glucose excursion (109%). The plasma Cmax of MK-4256 is determined from parallel mouse PK studies. MK-4256 achieves Cmax of 7, 88, and 493 nM, respectively, at 0.01, 0.1, and 1 mg/kg oral dose [1].

Chemical Properties

Molecular Weight	494.52
Formula	C₂₇H₂₃FN₈O
Cas No.	1104599-69-0
Smiles	Cc1nc(no1)[C@@]1(N[C@H](Cc2c1[nH]c1ccccc21)c1ncc([nH]1)-c1ccc(F)cc1)c1cnn(C)c1
Relative Density.	1.52 g/cm3 (Predicted)

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 100 mg/mL (202.22 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween-80+45% Saline: 4 mg/mL (8.09 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.0222 mL	10.1108 mL	20.2216 mL	101.1081 mL
5 mM	0.4044 mL	2.0222 mL	4.0443 mL	20.2216 mL
10 mM	0.2022 mL	1.0111 mL	2.0222 mL	10.1108 mL
20 mM	0.1011 mL	0.5055 mL	1.0111 mL	5.0554 mL
50 mM	0.0404 mL	0.2022 mL	0.4044 mL	2.0222 mL
100 mM	0.0202 mL	0.1011 mL	0.2022 mL	1.0111 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc